Co-Diagnostics (LTS:0A50) Tax Provision : $-0.06 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Co-Diagnostics Tax Provision?

Co-Diagnostics's tax provision for the three months ended in Dec. 2024 was $0.01 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.06 Mil.

Co-Diagnostics Tax Provision Historical Data

The historical data trend for Co-Diagnostics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Tax Provision Chart

Co-Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

-0.09

-8.98

4.61

2.78

-0.06

Co-Diagnostics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-3.83	-0.02	-0.02	-0.02	0.01

Co-Diagnostics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Co-Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (LTS:0A50) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

CODX:USA C97:Germany C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Co-Diagnostics Headlines

No Headlines